deltatrials
Completed PHASE2 INTERVENTIONAL 4-arm NCT03107182

Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer (OPTIMA-II)

A Phase II Trial of Nivolumab/Nab-paclitaxel/Carboplatin Induction Chemotherapy Followed by Response-stratified Locoregional Therapy for Patients With Locoregionally Advanced HPV-related Oropharyngeal Cancer- the OPTIMA II Trial

Sponsor: University of Chicago

Conditions HNSCC HPV-Related Squamous Cell Carcinoma
Interventions 5-FU Adjuvant RT Carboplatin Chemoradiotherapy Cisplatin Dexamethasone Diphenhydramine Famotidine Hydroxyurea Nivolumab Paclitaxel Transoral robotic surgery (TORS) nab-paclitaxel
Updated 16 times since 2017 Last updated: Apr 18, 2025 Started: Jun 27, 2017 Primary completion: Sep 6, 2024 Completion: Sep 6, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on HNSCC and HPV-Related Squamous Cell Carcinoma, this trial is completed. The trial is conducted by University of Chicago and has accumulated 16 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~May 2017 – ~Aug 2017 · 3 months · monthly snapshot~Aug 2017 – ~Mar 2018 · 7 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Nov 2019 · 17 months · monthly snapshot~Nov 2019 – ~Oct 2020 · 11 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Oct 2021 · 9 months · monthly snapshot~Oct 2021 – ~Dec 2021 · 2 months · monthly snapshot~Dec 2021 – ~May 2023 · 17 months · monthly snapshot~May 2023 – ~Sep 2023 · 4 months · monthly snapshot~Sep 2023 – ~Jul 2024 · 10 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Nov 2024 · 31 days · monthly snapshot~Nov 2024 – ~Jun 2025 · 7 months · monthly snapshot~Jun 2025 – present · 13 months · monthly snapshot

Change History

16 versions recorded

  1. Jun 2025 — Present [monthly]

    Completed PHASE2

  2. Nov 2024 — Jun 2025 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  3. Oct 2024 — Nov 2024 [monthly]

    Active Not Recruiting PHASE2

  4. Sep 2024 — Oct 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 11 earlier versions

  1. Sep 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  2. May 2023 — Sep 2023 [monthly]

    Active Not Recruiting PHASE2

  3. Dec 2021 — May 2023 [monthly]

    Active Not Recruiting PHASE2

  4. Oct 2021 — Dec 2021 [monthly]

    Active Not Recruiting PHASE2

  5. Jan 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE2

  6. Oct 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  7. Nov 2019 — Oct 2020 [monthly]

    Recruiting PHASE2

  8. Jun 2018 — Nov 2019 [monthly]

    Recruiting PHASE2

  9. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

  10. Aug 2017 — Mar 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  11. May 2017 — Aug 2017 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • University of Chicago
Data source: University of Chicago

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations